Feature|Articles|February 29, 2024

Itching for a Cure: The Psychosocial Impact of Prurigo Nodularis

In honor of Rare Disease Day, this exploration of prurigo nodularis highlights the skin disease’s psychosocial impact on patients around the world living with the condition.

When the US Food and Drug Administration (FDA) made its decision in 2022 to approve dupilumab (Dupixent) for patients with prurigo nodularis, patients in the US with the rare skin disease collectively heaved a sigh of relief.¹